These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28433474)

  • 41. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
    Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
    J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rituximab in late-onset myasthenia gravis is safe and effective.
    Sahai SK; Maghzi AH; Lewis RA
    Muscle Nerve; 2020 Sep; 62(3):377-380. PubMed ID: 32239711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19 in patients with myasthenia gravis.
    Anand P; Slama MCC; Kaku M; Ong C; Cervantes-Arslanian AM; Zhou L; David WS; Guidon AC
    Muscle Nerve; 2020 Aug; 62(2):254-258. PubMed ID: 32392389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab Treatment in
    Koul R; Al-Futaisi A; Abdelrahim R; Mani R; Abdwani R; Al-Asmi A
    Sultan Qaboos Univ Med J; 2018 May; 18(2):e223-e227. PubMed ID: 30210856
    [No Abstract]   [Full Text] [Related]  

  • 48. Successful treatment of refractory generalized myasthenia gravis with rituximab.
    Lebrun C; Bourg V; Tieulie N; Thomas P
    Eur J Neurol; 2009 Feb; 16(2):246-50. PubMed ID: 19146644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Refractory myasthenia gravis successfully treated with ofatumumab.
    Waters MJ; Field D; Ravindran J
    Muscle Nerve; 2019 Dec; 60(6):E45-E47. PubMed ID: 31509254
    [No Abstract]   [Full Text] [Related]  

  • 50. Anti-MuSK myasthenia gravis with prolonged remission.
    Bouwyn JP; Magnier P; Bédat-Millet AL; Ahtoy P; Maltête D; Lefaucheur R
    Neuromuscul Disord; 2016 Jul; 26(7):453-4. PubMed ID: 27161384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
    Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
    JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
    Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rituximab therapy for Morvan syndrome associated with myasthenia gravis.
    Weiss M
    Muscle Nerve; 2012 Jul; 46(1):139-40. PubMed ID: 22693003
    [No Abstract]   [Full Text] [Related]  

  • 55. Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes.
    Kefalopoulou ZM; Veltsista D; Germeni A; Lykouras D; Tsiamaki E; Chroni E
    Neurol Sci; 2024 Mar; 45(3):1233-1242. PubMed ID: 37831214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma.
    Takagi K; Yoshida A; Iwasaki H; Inoue H; Ueda T
    Ann Hematol; 2005 Aug; 84(8):548-50. PubMed ID: 15871017
    [No Abstract]   [Full Text] [Related]  

  • 57. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
    Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
    J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
    Ruan Z; Tang Y; Gao T; Li C; Guo R; Sun C; Huang X; Li Z; Chang T
    CNS Neurosci Ther; 2024 Jun; 30(6):e14793. PubMed ID: 38894580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey].
    Göl MF; Kara F; Boz M; Mutlu A; Karakullukçu S; Boz C
    Ideggyogy Sz; 2022 Sep; 75(9-10):351-359. PubMed ID: 36218113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rituximab in Myasthenia Gravis - Where do we stand?
    Siddiqi ZA; Khan W; Hussain FS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1013-1023. PubMed ID: 33566716
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.